SCHEMBL3782058

SCHEMBL3782058

Cc1ccnc(N2CCN(c3cc(C)ccn3)C2=O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.52
CCR5 P51681 1/20 0.52
CCR8 P51685 1/20 0.52
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
ALDH1A1 P00352 3/20 0.45
TSHR P16473 1/20 0.44
LMNA P02545 2/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 1/20 0.44
NOS3 P29474 1/20 0.44
NOS1 P29475 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21348668 0.86 CYP3A4 (0.43) CCR1CCR5CCR8CYP3A4CYP2C9
SCHEMBL20909892 0.81 CCR1 (0.47) CCR1CCR5CCR8CYP3A4CYP2C9
SCHEMBL10275026 0.80 CCR1 (0.50) CCR1CCR5CCR8CYP3A4CYP2C9
SCHEMBL15944233 0.79 CYP17A1 (0.74) CYP17A1
SCHEMBL12859179 0.78 CYP3A4 (0.48) CCR1CCR5CCR8CYP3A4CYP2C9
SCHEMBL1752197 0.77 CCR1 (0.47) CCR1CCR5CCR8CYP3A4CYP2C9
SCHEMBL18949715 0.76 GRIN2D (0.60) CCR1CCR5CCR8CYP3A4CYP2C9
SCHEMBL15344992 0.75 GRM5 (0.50) CCR1CCR5CCR8CYP3A4CYP2C9
SCHEMBL31036073 0.74 CYP3A4 (0.54) CCR1CCR5CCR8CYP3A4CYP2C9
SCHEMBL15491789 0.74 CYP3A4 (0.41) CCR1CCR5CCR8CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331326-A1 Inhibitors of CYP 17 NOVARTIS AG 2010-12-30 US claimed
US-RE45173-E1 Inhibitors of CYP 17 NOVARTIS AG (CH) 2014-09-30 US disclosed
US-20140228394-A1 INHIBITORS OF CYP 17 NOVARTIS AG (CH) 2014-08-14 US disclosed
US-8263635-B2 Inhibitors of CYP 17 NOVARTIS AG (CH) 2012-09-11 US disclosed
US-20100331326-A1 Inhibitors of CYP 17 NOVARTIS AG 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331326-A1 Inhibitors of CYP 17 CYP17A1, CYP21A2, CYP4A22 CCR1 3454/4885CCR5 2188/4885CCR8 3621/4885
US-20140228394-A1 INHIBITORS OF CYP 17 CYP17A1, CYP21A2, CYP4A22 CCR1 3454/4885CCR5 2188/4885CCR8 3621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.